Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First ST SW, Rochester, MN, USA.
Departamento de Gastroenterologia, Escuela de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile.
Hepatol Int. 2018 Feb;12(Suppl 1):24-33. doi: 10.1007/s12072-017-9798-x. Epub 2017 May 26.
The term gut-liver axis is used to highlight the close anatomical and functional relationship between the intestine and the liver. The intestine has a highly specialized epithelial membrane which regulates transport across the mucosa. Due to dysbiosis, impairment of the intestinal barrier and altered immunity status, bacterial products can reach the liver through the portal vein, where they are recognized by specific receptors, activate the immune system and lead to a proinflammatory response. Gut microbiota and bacterial translocation play an important role in the pathogenesis of chronic liver diseases, including alcoholic and non-alcoholic fatty liver disease, cirrhosis, and its complications, such as portal hypertension, spontaneous bacterial peritonitis and hepatic encephalopaty. The gut microbiota also plays a critical role as a modulator of bile acid metabolism which can also influence intestinal permeability and portal hypertension through the farnesoid-X receptor. On the other hand, cirrhosis and portal hypertension affect the microbiota and increase translocation, leading to a "chicken and egg" situation, where translocation increases portal pressure, and vice versa. A myriad of therapies targeting gut microbiota have been evaluated specifically in patients with chronic liver disease. Further studies targeting intestinal microbiota and its possible hemodynamic and metabolic effects are needed. This review summarizes the current knowledge about the role of gut microbiota in the pathogenesis of chronic liver diseases and portal hypertension.
“肠-肝轴”一词用于强调肠道和肝脏之间的紧密解剖和功能关系。肠道具有高度特化的上皮膜,可调节黏膜的物质转运。由于肠道菌群失调、肠道屏障受损和免疫状态改变,细菌产物可通过门静脉到达肝脏,在肝脏中被特定受体识别,激活免疫系统并引发炎症反应。肠道微生物群和细菌易位在慢性肝病(包括酒精性和非酒精性脂肪性肝病、肝硬化及其并发症,如门静脉高压、自发性细菌性腹膜炎和肝性脑病)的发病机制中起着重要作用。肠道微生物群还作为胆汁酸代谢的调节剂发挥关键作用,通过法尼醇 X 受体也可以影响肠道通透性和门静脉高压。另一方面,肝硬化和门静脉高压会影响微生物群并增加易位,导致“先有鸡还是先有蛋”的局面,即易位增加门静脉压力,反之亦然。针对肠道微生物群的多种治疗方法已专门在慢性肝病患者中进行了评估。需要进一步研究肠道微生物群及其可能的血流动力学和代谢作用。本文综述了目前关于肠道微生物群在慢性肝病和门静脉高压发病机制中的作用的相关知识。